Lung adenocarcinoma is the most common type of lung cancer. A close monitor of in vivo tumor development may help to better understand the pathogenesis and pathological processes of this disease. A bimodal imaging strategy has been developed, which is a very important tool to investigate the growth and metastasis of lung adenocarcinoma. In the present study, we used a combined labeling strategy in p53RE-luc-A549 cells via transfecting the reporter gene EGFP. In order to unambiguously identify the growth and metastasis of transfected A549 tumor cells, we established and observed subcutaneous and orthotopic xenografts in nude mice by in vivo bioluminescence and fluorescence imaging, which was verified by our post-mortem histological analysis. In vivo bioluminescence signal was observed for the progression of both subcutaneous and orthotopic xenografts in EGFP-p53RE-luc-A549 cells; in vivo fluorescence was only observed for the growth of subcutaneous xenograft of EGFP-p53RE-luc-A549 cells. Moreover, EGFP-p53RE-luc-A549 cells allow for the improved identification of implanted cells within host tissue during histological analysis. In conclusion, we presented a combined labeling strategy for bimodal A549 cell imaging which leads to improved detection of cellular grafts.
Introduction
Lung adenocarcinoma is the most common histological subtypes of lung cancer, the leading cancer-related cause of death in worldwide [1] . Although great progresses have been made in understanding the disease, animal models allowing for direct observation are essential to better understand the pathogenesis and pathological processes of lung adenocarcinoma. Indeed, some lung cancer models, such as orthotopic transplantation of human adenocarcinoma tumors in immune-deficient mice [2] [3] [4] , have been available for observation purpose; however, their performance to faithfully simulate the pathophysiology and histopathology of lung adenocarcinoma is yet unsatisfactory, for these models lack the ability to intuitively and dynamically observe the growth and metastasis of cancer in vivo. Therefore, new animal models are necessary to facilitate the detection of growth and metastasis of lung adenocarcinoma.
In the past decade, in vivo optical imaging technologies with bioluminescence and fluorescence have been developed, which allows for long-term, repeated, real-time in vivo monitoring the growth and metastasis of orthotopic transplantation tumor [5, 6] . Both bioluminescence and fluorescence imaging have their own characteristics, as demonstrated in the previous studies [7, 8] . Bioluminescence imaging with luciferase gene exhibits minimal background signals from the animal tissues, high specificity and precise quantification, and can be used to detect the deep tumor in vivo. Fluorescence imaging with green fluorescent reporter gene (GFP) or red fluorescent reporter gene (RFP) exhibits convenient, cheap, intuitive and diverse targets, and can be used to directly detect the cell behavior in vivo or in vitro by optical detection instrument, but cannot detect the deep tumor. Combined imaging technologies with bioluminescence and fluorescence might keep advantages of either one while being complementary to each other. In addition to allowing for long-term real-time detection, this combined imaging technologies can avoid sacrifice of the animals to assess the growth and metastasis of tumor in real time, which greatly reduced the experimental cost and differences among individual animals.
Realizing that the combined bioluminescence and fluorescence imaging holds significant promise in in vivo optical imaging in cancer research, we aimed to and succeeded in developing lung adenocarcinoma A549 cells labeled with luciferase gene and GFP together for
bioluminescence and fluorescence imaging. We also monitored the growth and metastasis of the transfected lung adenocarcinoma A549 cells by directly observing orthotopic/ subcutaneous xenografts transplanted in nude mice with in vivo combined bioluminescence and fluorescence imaging technologies.
Materials and Methods
Cell line and animals The p53RE-luc/A549 cell line, a luciferase expressing cell line derived from A549 human lung adenocarcinoma cells by stable transfection of p53RE-luc, was purchased from Xenogen Corporation (Alameda, USA). The cell line was maintained at 378C in RPMI-1640 medium (GibcoBRL, Oaisley, Scotland) supplemented with 10% fetal calf serum (Hyclone, Logan, USA) without antibiotics.
Female BALB/c nu/nu mice were purchased from Guangdong medical laboratory animal center (Guangdong, China), and were maintained in a pathogen-free environment. Twelve female mice (5-week old and weighting 17-18 grams) were randomly divided into two subgroups: six mice for subcutaneous xenografts and six mice for orthotopic xenografts. All procedures for animal care and use strictly followed the approved animal protocols and guidelines of the Animal Welfare Committee of Southern Medical University.
Lentiviral vector production and GFP transfection in p53RE-luc-A549 cells High-titer lentiviral vector stock was produced by co-transfecting 293T cells with 6.7 mg pFUGW (a lentiviral vector encoding enhanced GFP), 3.7 mg pMD2.G and 5 mg psPAX2 with lipofectamine 2000 (Invitrogen, CA, USA) in a 25 cm 2 corning flask. The transfected cells were first allowed to grow in serum free medium at 378C for 8 h, then washed and incubated again in growth medium containing 10% fetal serum for 48 h. Lentiviral vector was harvested by filtering the supernatants through 0.45 mm filters (Millipore, Billerica, USA), and used directly for GFP transfection in p53RE-luc-A549 cells (1Â10 5 cells in 35 mm diameter culture dishes). After 8 h transfection, p53RE-luc-A549 cells were washed and incubated again in growth medium containing 10% fetal serum. Reporter expression was determined at 40 h after transfection. Transfection stability and efficiency were estimated by analyzing the expression of GFP reporter using flow cytometric analysis (FACS, fluorescence-activated cell sorter). EGFP-transfected p53RE-luc-A549 (abbreviated as EGFP-p53RE-luc-A549) cells were then used for establishing xenografts in nude mice.
In vitro optical imaging Both in vivo and in vitro bioluminescence imaging was conducted on luciferase activity assessed by detection of photons using the Xenogen IVIS system (Xenogen, Alameda, USA). For in vitro luciferase assay, EGFP-p53RE-luc-A549 cells were planted on 96-well plates at an initial concentration of 50 cells/well, and allowed to grow overnight with regular growth medium. Then the regular medium was replaced with medium containing the D-luciferin (150 mg/ml). After treated for 2-5 min, bioluminescence images were taken using an IVIS Spectrum. Light outputs were quantified using Living Image 3.1 (Caliper Life Sciences, Alameda, USA) for future analysis.
In vitro fluorescence imaging was conducted on EGFP expression in EGFP-p53RE-luc-A549 cells, which was analyzed through FACS for GFP. The GFP fluorescence of EGFP-p53RE-luc-A549 cells in vitro was determined using an Olympus fluorescence microscope.
Subcutaneous and orthotopic xenografts
For subcutaneous implantation, 5Â10
6 EGFP-p53RE-luc-A549 cells were injected subcutaneously into the right flank of mice using a 26.5-gauge needle. Orthotopic xenografts were established following the standard protocol. Briefly, nu/nu mice were anesthetized with intraperitoneally (i.p.) injection of pentobarbital; a 5 mm skin incision was made at 1 mm tail side from the scapula; the left lung was exposed, by putting fat and muscle aside, to observe its movement through the pleura; a 29-gauge needle attached to a 1 ml insulin syringe was directly inserted through the intercostal space into the left lung at a depth of 4 mm; cell suspension (30 ml) that contains 5Â10 6 cells and 15 ml matrigel was injected into the lung parenchyma.
In vivo optical imaging Prior to in vivo imaging, the mice were anesthetized with isoflurane. For in vivo bioluminescence imaging, D-luciferin solution (150 mg/kg) was injected i.p. for both subcutaneous and orthotopic xenografts. After 15 min, mice were imaged using an IVIS Spectrum. Exposure times ranged from 10 to 30 s. Fluorescence imaging was obtained with an excitation wavelength of 465 nm and emission wavelength of 520 nm. Bioluminescent and fluorescent signals were simultaneously quantified using Living Image 3.1 (Caliper Life Sciences, Alameda, USA) on the 1st, 6th, 13th, 20th, 27th, 34th, and 41st (only for subcutaneous xenografts) day, respectively.
Histological analyses
After the last in vivo optical imaging, all transplanted mice were killed according to experimental protocol. Subcutaneous xenotransplanted tumors, orthotopic lung
Hematoxlyn and eosin (H&E) staining was performed. Fluorescence imaging from tumor tissue was detected with stereo fluorescence microscope (AZ-100, Nikon, Japan).
Results
In vitro stable and high expression of EGFP in transduced p53RE-luc-A549 cells EGFP-p53RE-luc-A549 cells had a strikingly bright GFP fluorescence and bioluminescence that remained stable after numerous passages [ Fig. 1(A,B) ]. The transfection efficiency of p53RE-luc-A549 with EGFP was 93.2% using FACS analysis [ Fig. 1(C) ]. Bioluminescence increased with the total number of cells per well in a broad dynamic range [ Fig. 1(B,D) ]; the minimum number of cells in suspension for detectable bioluminescence was 1000 cells per well [ Fig. 1(B) ].
In vivo optical imaging of subcutaneous and orthotopic xenografts of EGFP-p53RE-luc-A549 cells To test the ability of combined imaging technology for detecting the growth and metastasis of tumor in vivo, xenografts were generated by injecting EGFP-p53RE-luc-A549 cells subcutaneously into the right flank or orthotopically into the left lung of nude mice. Bioluminescence and fluorescence images were taken for assessing the growth and metastasis of implanted tumor cells. For subcutaneous transplantation, we found that the signals of bioluminescence and fluorescence increased over time, but no metastasis was found [ Fig. 2(A,C) ]. By contrast, for orthotopic transplantation, the signals of bioluminescence also increased as times went on [ Fig. 2(B,D) ], while fluorescent signals were hardly detected. Moreover, with bioluminescence imaging, the invasion and metastasis were observed in all nude mice with orthotopic transplantation [ Fig. 2(B) ]. Invasion was observed on day 6 and expanded from left lung to pleura followed by the right lung.
Metastasis in mice with orthotopic transplantation confirmed by histological analyses
To confirm the ability of combined imaging technology for detecting the metastasis of EGFP-p53RE-luc-A549 cells in nude mice, we conducted the following two studies. First, we performed histological analyses on H&E stained tissues. Both tumor tissue from nude mice with subcutaneous transplantation, and tumor tissue and pleura tissue from nude mice with orthotopic transplantation showed numerous tumor cells [ Fig. 3(A,C) ]. No metastasis was found in nude Combined bioluminescence and fluorescence for in vivo imaging mice with subcutaneous transplantation. Pleura and right lung from nude mice with orthotopic transplantation were infiltrated with sheets of poorly differentiated neoplastic cells [ Fig. 3(C) ]. Second, we performed fluorescence analyses on H&E stained tissues. Using stereo fluorescence microscopy, fluorescent signals were only detected in tumor tissue but not in any other tissue, obtained from nude mice with subcutaneous transplantation [ Fig. 3(B) ]. Fluorescent signals were commonly detected in right lung and pleura, which were obtained from nude mice with orthotopic transplantation [ Fig. 3(D) ]. This agreed with the results from histological analyses on H&E stained tissues. In summary, our combined bioluminescence and fluorescence imaging could effectively detect metastases in mice.
Discussion
Xenograft models provide a useful platform for studying tumor growth, invasion, metastasis, angiogenesis, and effects of tumor microenvironment [9, 10] . A large drawback to xenograft models is the difficulty in continuously and dynamically predicting tumor progression in vivo in time [11, 12] . Consequently, it is hard to evaluate tumor progression such as growth, diffusion, and metastasis. Since both bioluminescence and fluorescence imaging have their own specific advantages and disadvangtages [13] , co-expressing bioluminescence with fluorescence could be highly beneficial if the combination can keep their advantages and be complementary to each other. Our work here shows that combined bioluminescence and fluorescence imaging provide a unique model to visualize lung tumor progression in real time in a live animal.
In this study, we first generated EGFP-transduced p53RE-luc-A549 cell line using EGFP, p53RE-luc-A549 cell line and lentiviral technology. We found that both bioluminescence and fluorescence were stably co-expressed in EGFP-p53RE-luc-A549 cells. EGFP reporter was used to measure transfection efficiency and to sort the transfected Combined bioluminescence and fluorescence for in vivo imaging cells at multiple time points by FACS analysis. The transfection efficiency of p53RE-luc-A549 with EGFP could reach 93.2%. These two genes remained stably expressed after numerous passages. The reason for this high transfection efficiency is that EGFP reporter is easily transfected into cells and hardly affected by effector gene [14] . The successful transfection and the co-expression of these two proteins were validated by in vitro imaging with both inverted fluorescence microscope and Xenogen IVIS system. EGFP-p53RE-luc-A549 cells exhibited not only a strong fluorescence signal, but also the bioluminescence signal. This finding suggests that co-expression of bioluminescence with fluorescence permits the direct visualization of gene activity in living cells in vitro. Moreover, we also demonstrated a strong correlation between cell number and bioluminescence intensity. All these findings indicated not only the success of stable co-expression of bioluminescence and fluorescence in A549 cells, but also the feasibility of this cell line as a better tool to investigate the growth and metastasis of lung adenocarcinoma in vivo.
We also found that co-expression of bioluminescence and fluorescence contributed to overcoming the defects of fluorescence imaging. Both bioluminescence and fluorescence signals could be detected in subcutaneous xenografted tumors. However, bioluminescence signals, but not fluorescence signals, were detected in orthotopic xenografted tumors. This finding can be attributed to bioluminescence imaging which can detect relatively weak signals from deep tissue with high signal-to-background ratio in contrast to fluorescence imaging. Indeed, bioluminescence imaging has already been shown to be important for detecting orthotopic xenografted tumors or metastatic tumors in deep tissue [15] . Our study also showed that the intensity of bioluminescence signal increased with the growth and metastasis of orthotopic xenografted EGFP-p53RE-luc-A549 cells.
Beyond that, one advantage of the fluorescence imaging techniques described here is to avoid the complex procedures of bioluminescence imaging for detecting cells/ tissues in vitro, since visualization of fluorescent reporters does not require the administration of a substrate, and can be used in both live and fixed cells/tissues [16] . Our study confirmed that stereo fluorescence microscopy could directly detect the fluorescent signals of xenograft and metastatic tumors, when they were removed from nude mice with implantation.
Similar to this study, the same technology has been applied to several cell lines such as MCF-7, B16-F10, PacMetUT1, and human embryonic stem cells (hESC), in which bioluminescence and fluorescence can be Combined bioluminescence and fluorescence for in vivo imaging co-expressed. In addition to non-invasive in vivo visualization of tumor progression of the transplanted cells [16] [17] [18] , this approach may provide differentiated data for various tumors.
In summary, we developed a novel approach to combine bioluminescence and fluorescence imaging to directly observe in vivo growth and metastasis of xenografted A549 cells in nude mice. We also verified this approach with stereo fluorescence microscopy and histological analysis. We believe such combined imaging technology will be a revolutionary tool in cancer prognosis and cancer therapy.
